PATENT COOPERATION TREATY

From the INTERNATIONAL PRELIMINARY I To: GEOFFREY L. MELNICK G.E. EHRLICH (1995) LTD. 11 MENACHEM BEGIN STREET RAMAT GAN, 52 521 ISRAEL	RECEIV 11 SEP 20	NOT NOT	PCT FICATION OF TRANSMITTAL OF TERNATIONAL PRELIMINARY EPORT ON PATAENTABILITY or II of the Patent Cooperation Treaty) (PCT Rule 71.1)	
		Date of mailing (day/month/year		
Applicant's or agent's file reference 27867		IN	MPORTANT NOTIFICATION	
International application No.	International filing date (da	xy/month/year)	Priority date (day/month/year)	
PCT/IL04/00305	01 April 2004 (01.04.2004)		04 April 2003 (04.04.2003)	
Applicant				
BIOVIEW LTD.				

- The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary report on patentability and its annexes, if any, established on the international application.
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed invention is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the IPEA/ US

Mail Stop PCT, Attn: IPEA/US Commissioner for Patents P.O. Box 1450

Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230

Authorized officer

7. Roberts for

Form PCT/IPEA/416 (January 2004)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER A	CTRON	See Form PCT/IPEA/416	
27867	TORTORIALA		See Politi FC1/1FEA/410	
International application No.	International filing date	(day/month/year)	Priority date (day/month/year)	
PCT/IL04/00305 01 April 2004 (01.04.2			04 April 2003 (04.04.2003)	
International Patent Classification (IPC)	International Patent Classification (IPC) or national classification and IPC			
IPC(7): G01N 33/53 and US C1.: 435/7.1. 7.21, 7.7,7.9, 40.5, 40.51, 40.52				
Applicant				
BIOVIEW LTD.				
 This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. 				
2. This REPORT consists of	a total of <u>O</u> sheets,	including this cover s	heet.	
This report is also accomp	anied by ANNEXES, o	omprising:		
a. 🔀 (sent to the applica	nt and to the Internatio	nal Bureau) a total of	sheets, as follows:	
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions). sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as				
	tem 4 of Box No. I and		dicate type and number of electronic	
carrier(s))	е тиетшиони вигеи	i oray) a total of (file	incate type and number of electronic	
, containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).				
4. This report contains indicate	tions relating to the foll	owing items:		
Box No. I Bas	sis of the report			
Box No. II Pri	ority			
	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			
Box No. IV Lac	ck of unity of invention			
	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
Box No. VI Cer	Box No. VI Certain documents cited			
Box No. VII Certain defects in the international application				
Box No. VIII Certain observations on the international application			tion	
Date of submission of the demand		Date of completion of this report		
21 April 2005 (21.04.2005)		04 August 2005 (04.08.2005)		
Name and mailing address of the IPEA/ US		Authorized officer		
Mail Stop PCT, Attn: IPEA/US Commissioner for Patents		Sheela J. Huff	. Roberts for	
P.O. Box 1450 Alexandria, Virginia 22313-1450	,	CY	. 1000 23 pc/	
Facsimile No. (703) 305-3230		Telephone No. 571-27	2-1600	

Form PCT/IPEA/409 (cover sheet)(January 2004)

International application No.	
PCT/H 04/00305	

Box No. I B	asis of the report
	to the language, this report is based on the international application in the language in which it was otherwise indicated under this item.
	eport is based on translations from the original language into the following language, is the language of a translation furnished for the purposes of:
i	nternational search (under Rules 12.3 and 23.1(b))
	ublication of the international application (under Rule 12.4)
i	nternational preliminary examination (under Rules 55.2 and/or 55.3)
furnished to	to the elements of the international application, this report is based on <i>(replacement sheets which have been he receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" nnexed to this report):</i>
the int	ernational application as originally filed/furnished
the des	scription:
	1-34 as originally filed/furnished
	NONE received by this Authority on
pages*	NONE received by this Authority on
the cla	ims:
pages	NONE as originally filed/furnished
	NONE as amended (together with any statement) under Article 19
	35-45 received by this Authority on 21 April 2005 (21.04.2005)
pages*	NONE received by this Authority on
the dra	wings:
	1-4 as originally filed/furnished
	NONE received by this Authority on
pages*	NONE received by this Authority on
a seque	ence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.
3. The an	endments have resulted in the cancellation of:
\boxtimes	the description, pages none
\bowtie	the claims, Nos_none
Ħ	the drawings, sheets/figs_none
Ħ	the sequence listing (specify): none
	any table(s) related to the sequence listing (specify):
4. This rep	ort has been established as if (some of) the amendments annexed to this report and listed below had not been made, by have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Ruie 70.2(c)).
	the description, pages
	the claims, Nos
	the drawings, sheets/figs
	the sequence listing (specify):
	any table(s) related to the sequence listing (specify):
* If item 4 appli	es, some or all of those sheets may be marked "superseded."

International application No.

PCT/IL04/00305

Box No.	II Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
	ions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to ially applicable have not been examined in respect of:
	he entire international application
\boxtimes	laims Nos. <u>72-75</u>
	pecause:
	the said international application, or the said claim Nos relate to the following subject matter which loes not require an international preliminary examination (specify):
	he description, claims or drawings <i>(indicate particular elements below)</i> or said claims Nos are so inclear that no meaningful opinion could be formed <i>(specify)</i> :
	ne claims, or said claims Nos are so inadequately supported by the description that no meaningful pinion could be formed.
	o international search report has been established for said claims Nos. 72-75
	ne nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:
	e written form has not been furnished
	does not comply with the standard
	e computer readable form has not been furnished
	does not comply with the standard
	e tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not amply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.
	ee Supplemental Box for further details.
DOT	DEA /409 (Box No. 11D. (January 2004)

International application No. PCT/IL04/00305

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
. Statement				
Novelty (N)	Claims 6,9,14-18,24,26-27,29-30,32-71	YES		
	Claims <u>1-5,7-8,10-13,19-23,25,28,31</u>	NC		
Inventive Step (IS)	Claims 6,9,14-15,17-18,24,26-27,29,30,32-71	YE		
	Claims 1-5, 7-8,10-13,16,19-23,25,28,31	NC		
Industrial Applicability (IA)	Claims 1-71	YE		
	Claims NONE	NC		
. Citations and Explanations (Rule 70.7)				
ease See Continuation Sheet				
	4			

Form PCT/IPEA/409 (Box No. V) (January 2004)

International application No. PCT/IL04/00305

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of:

V. 2. Citations and Explanations:

Claims 1-5, 7, 10-13, 19-23, 25, 28 and 31 lack novelty under PCT Article 33(2) as being anticipated by McCORMICK et al.

This reference describes the assessment of HER2 using two different stains (immunohistochemical and fluorescence in situ hybridization. The analysis was done in formalin-fixed, paraffin-embedded breast tumors.

Applicant argues that in the instant invention the same sample is stained twice and in the reference two different sections are used. Applicant is arguing limitations not found in the claims.

Claims 1-5, 8, 19-23 and 25 lack novelty under PCT Article 33(2) as being anticipated by VAN AGTHOVAN et al.

This reference describes the assessment of malignant breast tissues using dual staining immunohistochemistry.

Applicant argues that the reference uses a single imaging device and the instant invention uses two. The claims do not recite that the imaging devices are different.

Claims 1-7, 10, 13, 16, 19-23, 25, 28 and 31 lack an inventive step under PCT Article 33(3) as being obvious over BEUG et al.

This reference describes the use of histochemical staining with anti-TGFbeta antibodies and the determination of mRNA level using in situ hybridization in tumor cells.

The only difference between the reference and the instant invention is that the reference did not show use the assays.

In view of the suggestion in the reference, it would have been obvious to one of ordinary skill in the art at the time of applicant's invention to use the suggested assays to determine the production of TGFbeta1 in tumor cells.

Applicant argues that the imaging is done on different sections. Again, applicant is arguing limitations not in the claims.


Claims 1-5, 7, 11, 13, 19-23, 25 and 31 lack novelty under PCT Article 33(2) as being anticipated by HENNING et al.

This reference describes the use of cytochemical and histochemical staining to determine molecular markers for tumors in uterine cervical smears. The assays were detected using chromogenic or fluorescent detection. The examples describes the use of an antibody and DNA probe or the use of two antibodies.

Applicant argues that the reference uses a single imaging device to simultaneously view the sample and the instant invention

International application No. PCT/IL04/00305

uses two. The claims do not recite that the imaging devices are different. Furthermore, the claims also read on simultaneous detection.				
Claims 1-71 meet the criteria set out in PCT Article 33(4), and thus the industrial applicability because the subject matter claimed can be made or used in industry. Claims 6, 9, 14-15, 17-18, 24, 26, 27, 29, 30 and 32-71 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the claimed invention.				
			•	



WHAT IS CLAIMED IS:

- 1. A method of identifying cancerous cells in a biological sample comprising:
- (a) staining nucleated cells of the biological sample with at least two stains to thereby obtain stained nucleated cells, and;
- (b) sequentially and/or simultaneously exposing said stained nucleated cells to at least two imaging modes, to thereby identify the cancerous cells in the biological sample.
- 2. The method of claim 1, wherein each imaging mode of said at least two imaging modes is specific to a stain of said at least two stains.
- 3. The method of claim 1, wherein the cancerous cells are associated with a cancer selected from the group consisting of leukemia, lymphoma, brain cancer, cerebrospinal cancer, bladder cancer, prostate cancer, breast cancer, cervix cancer, uterus cancer, ovarian cancer, kidney cancer, esophagus cancer, lung cancer, colon cancer, pancreatic cancer, and melanoma.
- 4. The method of claim 1, wherein the biological sample is selected from the group consisting of bone marrow cells, lymph nodes cells, peripheral blood, cerebrospinal fluid, urine, effusions, fine needle aspirates, peripheral blood scrapings, paraffin embedded tissues, and frozen sections.
- 5. The method of claim 1, wherein each stain of said at least two stains is independently selected from the group consisting of a morphological stain, an immunological stain, an activity stain, a cytogenetical stain, *in situ* hybridization stain and a DNA stain.
- 6. The method of claim 5, wherein said morphological stain is selected from the group consisting of May-Grünwald-Giemsa stain, Giemsa stain, Papanicolau stain, Hematoxylin-Eosin stain and DAPI stain.

- 7. The method of claim 5, wherein said immunological stain is selected from the group consisting of fluorescently labeled immunohistochemistry, radiolabeled immunohistochemistry and immunocytochemistry.
- 8. The method of claim 5, wherein said activity stain is selected from the group consisting of cytochemical stain and substrate binding assay stain.
- 9. The method of claim 5, wherein said cytogenetical stain is selected from the group consisting of G-banding stain, R-banding stain, Q-banding stain, and C-banding stain.
- 10. The method of claim 5, wherein said *in situ* hybridization stain is selected from the group consisting of fluorescent *in situ* hybridization (FISH) stain, radiolabeled *in situ* hybridization stain, Digoxigenin labeled *in situ* hybridization stain and biotinylated *in situ* hybridization stain.
- 11. The method of claim 5, wherein said DNA stain is a DNA-binding fluorescent dye.
- 12. The method of claim 1, wherein a first stain of said at least two stains is a morphological stain and a second stain of said at least two stains is selected from the group consisting of an immunological stain, an activity stain, an *in situ* hybridization stain, and a DNA stain.
- 13. The method of claim 1, wherein a first stain of said at least two stains is an immunological stain and a second stain of said at least two stains is selected from the group consisting of a morphological stain, an activity stain, an *in situ* hybridization stain, and a DNA stain.
- 14. The method of claim 1, wherein a first stain of said at least two stains is an activity stain and a second stain of said at least two stains is selected from the group


DEEMUS 31 APR 2005

consisting of a morphological stain, an immunological stain, an *in situ* hybridization stain, and a DNA stain.

- 15. The method of claim 1, wherein a first stain of said at least two stains is a cytogenetical stain and a second stain of said at least two stains is selected from the group consisting of an immunological stain, an *in situ* hybridization stain, and a DNA stain.
- 16. The method of claim 1, wherein a first stain of said at least two stains is an *in situ* hybridization stain and a second stain of said at least two stains is a DNA stain.
- 17. The method of claim 1, wherein a first stain of said at least two stains is a DNA stain and a second stain of said at least two stains is an *in situ* hybridization stain.
- 18. The method of claim 1, wherein step (b) is effected using an automated cell imaging device capable of at least dual imaging.
- 19. A method of diagnosing cancer in a subject, the method comprising:
- (a) obtaining a biological sample from the subject;
- (b) staining nucleated cells of said biological sample with at least two stains to thereby obtain stained nucleated cells, and;
- (c) sequentially and/or simultaneously exposing said stained nucleated cells to at least two imaging modes, to thereby determine the presence or absence of cancerous cells within said stained nucleated cells, wherein presence of said cancerous cells is indicative of a positive cancer diagnosis.
- 20. The method of claim 19, wherein each imaging mode of said at least two imaging modes is specific to a stain of said at least two stains.
- 21. The method of claim 19, wherein the cancer is selected from the group consisting of leukemia, lymphoma, brain cancer, cerebrospinal cancer, bladder cancer, prostate

cancer, breast cancer, cervix cancer, uterus cancer, ovarian cancer, kidney cancer, esophagus cancer, lung cancer, colon cancer, pancreatic cancer, and melanoma.


- 22. The method of claim 19, wherein said biological sample is selected from the group consisting of bone marrow cells, lymph nodes cells, peripheral blood, cerebrospinal fluid, urine, effusions, fine needle aspirates and/or peripheral blood scrapings, paraffin embedded tissues, and frozen sections.
- 23. The method of claim 19, wherein each stain of said at least two stains is independently selected from the group consisting of a morphological stain, an immunological stain, an activity stain, a cytogenetical stain, in situ hybridization stain and a DNA stain.
- 24. The method of claim 23, wherein said morphological stain is selected from the group consisting of May-Grünwald-Giemsa stain, Giemsa stain, Papanicolau stain, Hematoxylin-Eosin stain and DAPI stain.
- 25. The method of claim 23, wherein said immunological stain is selected from the group consisting of fluorescently labeled immunohistochemistry, radiolabeled immunohistochemistry and immunocytochemistry.
- 26. The method of claim 23, wherein said activity stain is selected from the group consisting of cytochemical stain and substrate binding assay stain.
- 27. The method of claim 23, wherein said cytogenetical stain is selected from the group consisting of G-banding stain, R-banding stain, Q-banding stain, and C-banding stain.
- 28. The method of claim 23, wherein said *in situ* hybridization stain is selected from the group consisting of fluorescent *in situ* hybridization (FISH) stain, radiolabeled *in situ* .



hybridization stain, Digoxigenin labeled *in situ* hybridization stain and biotinylated *in situ* hybridization stain.

- 29. The method of claim 23, wherein said DNA stain is a DNA-binding fluorescent dye.
- 30. The method of claim 19, wherein a first stain of said at least two stains is a morphological stain and a second stain of said at least two stains is selected from the group consisting of an immunological stain, an activity stain, an *in situ* hybridization stain, and a DNA stain.
- 31. The method of claim 19, wherein a first stain of said at least two stains is an immunological stain and a second stain of said at least two stains is selected from the group consisting of a morphological stain, an activity stain, an *in situ* hybridization stain, and a DNA stain.
- 32. The method of claim 19, wherein a first stain of said at least two stains is an activity stain and a second stain of said at least two stains is selected from the group consisting of a morphological stain, an immunological stain, an *in situ* hybridization stain, and a DNA stain.
- 33. The method of claim 19, wherein a first stain of said at least two stains is a cytogenetical stain and a second stain of said at least two stains is selected from the group consisting of an immunological stain, an *in situ* hybridization stain, and a DNA stain.
- 34. The method of claim 19, wherein a first stain of said at least two stains is an *in situ* hybridization stain and a second stain of said at least two stains is a DNA stain.
- 35. The method of claim 19, wherein a first stain of said at least two stains is a DNA stain and a second stain of said at least two stains is an *in situ* hybridization stain.

- 36. The method of claim 19, wherein step (b) is effected using an automated cell imaging device capable of at least dual imaging.
- 37. A method of identifying transitional cell carcinoma cells in a urine sample comprising:
- (a) staining nucleated cells of the urine sample with at least two stains to thereby obtain stained nucleated cells, and;
- (b) sequentially and/or simultaneously exposing said stained nucleated cells to at least two imaging modes, to thereby identify the transitional cell carcinoma cells in the urine sample.
- 38. The method of claim 37, wherein each imaging mode of said at least two imaging modes is specific to a stain of said at least two stains.
- 39. The method of claim 37, wherein the transitional cell carcinoma cells are associated with bladder cancer and/or kidney cancer.
- 40. The method of claim 37, wherein the urine sample is obtained via voided urine or catheterization.
- 41. The method of claim 37, wherein each stain of said at least two stains is independently selected from the group consisting of a morphological stain, an immunological stain, an activity stain, a cytogenetical stain, *in situ* hybridization stain and a DNA stain.
- 42. The method of claim 41, wherein said morphological stain is selected from the group consisting of May-Grünwald-Giemsa stain, Giemsa stain, Papanicolau stain, Hematoxylin-Eosin stain and DAPI stain.



- 43. The method of claim 41, wherein said immunological stain is selected from the group consisting of fluorescently labeled immunohistochemistry, radiolabeled immunohistochemistry and immunocytochemistry.
- 44. The method of claim 41, wherein said activity stain is selected from the group consisting of cytochemical stain and substrate binding assay stain.
- 45. The method of claim 41, wherein said cytogenetical stain is selected from the group consisting of G-banding stain, R-banding stain, Q-banding stain, and C-banding stain.
- 46. The method of claim 41, wherein said *in situ* hybridization stain is selected from the group consisting of fluorescent *in situ* hybridization (FISH) stain, radiolabeled *in situ* hybridization stain, Digoxigenin labeled *in situ* hybridization stain and biotinylated *in situ* hybridization stain.
- 47. The method of claim 41, wherein said DNA stain is a DNA-binding fluorescent dye.
- 48. The method of claim 37, wherein a first stain of said at least two stains is a morphological stain and a second stain of said at least two stains is selected from the group consisting of an immunological stain, an activity stain, an *in situ* hybridization stain, and a DNA stain.
- 49. The method of claim 37, wherein a first stain of said at least two stains is an immunological stain and a second stain of said at least two stains is selected from the group consisting of a morphological stain, an activity stain, an *in situ* hybridization stain, and a DNA stain.
- 50. The method of claim 37, wherein a first stain of said at least two stains is an activity stain and a second stain of said at least two stains is selected from the group


consisting of a morphological stain, an immunological stain, an *in situ* hybridization stain, and a DNA stain.

- 51. The method of claim 37, wherein a first stain of said at least two stains is a cytogenetical stain and a second stain of said at least two stains is selected from the group consisting of an immunological stain, an *in situ* hybridization stain, and a DNA stain.
- 52. The method of claim 37, wherein a first stain of said at least two stains is an *in situ* hybridization stain and a second stain of said at least two stains is a DNA stain.
- 53. The method of claim 37, wherein a first stain of said at least two stains is a DNA stain and a second stain of said at least two stains is an *in situ* hybridization stain.
- 54. The method of claim 37, wherein step (b) is effected using an automated cell imaging device capable of at least dual imaging.
- 55. A method of diagnosing bladder cancer in a subject, the method comprising:
- (a) obtaining a urine sample from the subject;
- (b) staining nucleated cells of said urine sample with at least two stains to thereby obtain stained nucleated cells, and;
- (c) sequentially and/or simultaneously exposing said stained nucleated cells to at least two imaging modes, to thereby determine the presence or absence of cancerous cells within said stained nucleated cells, wherein presence of said cancerous cells is indicative of a positive cancer diagnosis.
- 56. The method of claim 55, wherein each imaging mode of said at least two imaging modes is specific to a stain of said at least two stains.
- 57. The method of claim 55, wherein the urine sample is obtained via voided urine or catheterization.

- 58. The method of claim 55, wherein each stain of said at least two stains is independently selected from the group consisting of a morphological stain, an immunological stain, an activity stain, a cytogenetical stain, in situ hybridization stain and a DNA stain.
- 59. The method of claim 58, wherein said morphological stain is selected from the group consisting of May-Grünwald-Giemsa stain, Giemsa stain, Papanicolau stain, Hematoxylin-Eosin stain and/or DAPI stain.
- 60. The method of claim 58, wherein said immunological stain is selected from the group consisting of fluorescently labeled immunohistochemistry, radiolabeled immunohistochemistry and immunocytochemistry.
- 61. The method of claim 58, wherein said activity stain is selected from the group consisting of cytochemical stain and substrate binding assay stain.
- 62. The method of claim 58, wherein said cytogenetical stain is selected from the group consisting of G-banding stain, R-banding stain, Q-banding stain, and C-banding stain.
- 63. The method of claim 58, wherein said *in situ* hybridization stain is selected from the group consisting of fluorescent *in situ* hybridization (FISH) stain, radiolabeled *in situ* hybridization stain, Digoxigenin labeled *in situ* hybridization stain and biotinylated *in situ* hybridization stain.
- 64. The method of claim 58, wherein said DNA stain is a DNA-binding fluorescent dye.
- 65. The method of claim 55, wherein a first stain of said at least two stains is a morphological stain and a second stain of said at least two stains is selected from the

group consisting of an immunological stain, an activity stain, an in situ hybridization stain, and a DNA stain.

- 66. The method of claim 55, wherein a first stain of said at least two stains is an immunological stain and a second stain of said at least two stains is selected from the group consisting of a morphological stain, an activity stain, an *in situ* hybridization stain, and a DNA stain.
- 67. The method of claim 55, wherein a first stain of said at least two stains is an activity stain and a second stain of said at least two stains is selected from the group consisting of a morphological stain, an immunological stain, an *in situ* hybridization stain, and a DNA stain.
- 68. The method of claim 55, wherein a first stain of said at least two stains is a cytogenetical stain and a second stain of said at least two stains is selected from the group consisting of an immunological stain, an *in situ* hybridization stain, and a DNA stain.
- 69. The method of claim 55, wherein a first stain of said at least two stains is an *in situ* hybridization stain and a second stain of said at least two stains is a DNA stain.
- 70. The method of claim 55, wherein a first stain of said at least two stains is a DNA stain and a second stain of said at least two stains is an *in situ* hybridization stain.
- 71. The method of claim 55, wherein step (b) is effected using an automated cell imaging device capable of at least dual imaging.
- 72. A method of identifying cancerous cells in a biological sample comprising:
- (a) staining nucleated cells of the biological sample with a first stain to thereby obtain stained nucleated cells;
- (b) exposing said stained nucleated cells to one imaging mode;



- (c) staining said stained nucleated cells with a second stain to thereby obtain stained nucleated cells with a second stain; and
- (d) exposing said stained nucleated cells with said second stain to a second imaging mode to thereby identify the cancerous cells in the biological sample.
- 73. The method of claim 72, further comprising a step of de-staining following said staining with said first stain to thereby remove residual dye of said first stain.
- 74. A method of identifying cancerous cells in a biological sample comprising:
- (a) staining nucleated cells of the biological sample with at least two stains, wherein at least one of said at least two stains is a morphological stain, to thereby obtain stained nucleated cells; and
- (b) sequentially and/or simultaneously exposing said stained nucleated cells to at least two imaging modes, to thereby identify the cancerous cells in the biological sample.
- 75. The method of claim 74, wherein said morphological stain is selected from the group consisting of May-Grünwald-Giemsa stain, Giemsa stain, Papanicolau stain, Hematoxylin-Eosin stain and DAPI stain.